{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:56:52Z","timestamp":1791921412605,"version":"4.3.4"},"reference-count":75,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T00:00:00Z","timestamp":1706227200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>A primary concern in vaccine development is safety, particularly avoiding an excessive immune reaction in an otherwise healthy individual. An accurate prediction of vaccine reactogenicity using in vitro assays and computational models would facilitate screening and prioritization of novel candidates early in the vaccine development process. Using the modular in vitro immune construct model of human innate immunity, PBMCs from 40 healthy donors were treated with 10 different vaccines of varying reactogenicity profiles and then cell culture supernatants were analyzed via flow cytometry and a multichemokine\/cytokine assay. Differential response profiles of innate activity and cell viability were observed in the system. In parallel, an extensive adverse event (AE) dataset for the vaccines was assembled from clinical trial data. A novel reactogenicity scoring framework accounting for the frequency and severity of local and systemic AEs was applied to the clinical data, and a machine learning approach was employed to predict the incidence of clinical AEs from the in vitro assay data. Biomarker analysis suggested that the relative levels of IL-1B, IL-6, IL-10, and CCL4 have higher predictive importance for AE risk. Predictive models were developed for local reactogenicity, systemic reactogenicity, and specific individual AEs. A forward-validation study was performed with a vaccine not used in model development, Trumenba (meningococcal group B vaccine). The clinically observed Trumenba local and systemic reactogenicity fell on the 26th and 93rd percentiles of the ranges predicted by the respective models. Models predicting specific AEs were less accurate. Our study presents a useful framework for the further development of vaccine reactogenicity predictive models.<\/jats:p>","DOI":"10.4049\/jimmunol.2300185","type":"journal-article","created":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T14:13:07Z","timestamp":1706278387000},"page":"904-916","source":"Crossref","is-referenced-by-count":17,"title":["A Predictive Model of Vaccine Reactogenicity Using Data from an In Vitro Human Innate Immunity Assay System"],"prefix":"10.1093","volume":"212","author":[{"suffix":"III","given":"Robert H","family":"Pullen","sequence":"first","affiliation":[{"name":"Preclinical Safety , Sanofi, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Sassano","sequence":"additional","affiliation":[{"name":"Sanofi Pasteur VaxDesign , Sanofi, Orlando, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6295-5301","authenticated-orcid":false,"given":"Pankaj","family":"Agrawal","sequence":"additional","affiliation":[{"name":"Sanofi Pasteur VaxDesign , Sanofi, Orlando, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6605-1312","authenticated-orcid":false,"given":"John","family":"Escobar","sequence":"additional","affiliation":[{"name":"Sanofi Pasteur VaxDesign , Sanofi, Orlando, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mounir","family":"Chehtane","sequence":"additional","affiliation":[{"name":"Sanofi Pasteur VaxDesign , Sanofi, Orlando, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6528-4399","authenticated-orcid":false,"given":"Brian","family":"Schanen","sequence":"additional","affiliation":[{"name":"Sanofi Pasteur VaxDesign , Sanofi, Orlando, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Donald R","family":"Drake","sequence":"additional","affiliation":[{"name":"Sanofi Pasteur VaxDesign , Sanofi, Orlando, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2631-6164","authenticated-orcid":false,"given":"Ernesto","family":"Luna","sequence":"additional","affiliation":[{"name":"Sanofi Pasteur VaxDesign , Sanofi, Orlando, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0449-2730","authenticated-orcid":false,"given":"Richard J","family":"Brennan","sequence":"additional","affiliation":[{"name":"Preclinical Safety , Sanofi, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,1,26]]},"reference":[{"key":"2025020405460543900_r1","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1080\/21645515.2019.1697110","article-title":"Methods for predicting vaccine immunogenicity and reactogenicity","volume":"16","author":"Gonzalez-Dias","year":"2020","journal-title":"Hum. Vaccin. Immunother."},{"key":"2025020405460543900_r2","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41541-019-0132-6","article-title":"The how\u2019s and what\u2019s of vaccine reactogenicity","volume":"4","author":"Herv\u00e9","year":"2019","journal-title":"NPJ Vaccines"},{"key":"2025020405460543900_r3","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1002\/art.40071","article-title":"Review: cytokine storm syndrome: looking toward the precision medicine era","volume":"69","author":"Behrens","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"2025020405460543900_r4","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMoa063842","article-title":"Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412","volume":"355","author":"Suntharalingam","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"2025020405460543900_r5","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1172\/JCI35382","article-title":"The calm after the cytokine storm: lessons from the TGN1412 trial","volume":"118","author":"St. Clair","year":"2008","journal-title":"J. Clin. Invest."},{"key":"2025020405460543900_r6","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jconrel.2021.03.043","article-title":"The dawn of mRNA vaccines: the COVID-19 case","volume":"333","author":"Verbeke","year":"2021","journal-title":"J. Control. Release"},{"key":"2025020405460543900_r7","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1080\/14760584.2022.2098719","article-title":"Comparing reactogenicity of COVID-19 vaccines: a systematic review and meta-analysis","volume":"21","author":"Sutton","year":"2022","journal-title":"Expert Rev. Vaccines"},{"key":"2025020405460543900_r8","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/S0165-5728(01)00421-0","article-title":"Proinflammatory and regulatory cytokine production associated with innate and adaptive immune responses in children with autism spectrum disorders and developmental regression","volume":"120","author":"Jyonouchi","year":"2001","journal-title":"J. Neuroimmunol."},{"key":"2025020405460543900_r9","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0165-5728(02)00468-X","article-title":"IL-1\u03b2-dependent neurological effects of the whole cell pertussis vaccine: a role for IL-1-associated signalling components in vaccine reactogenicity","volume":"136","author":"Armstrong","year":"2003","journal-title":"J. Neuroimmunol."},{"key":"2025020405460543900_r10","first-page":"18","article-title":"The blood brain barrier and the role of cytokines in neuropsychiatry","volume":"6","author":"Yarlagadda","year":"2009","journal-title":"Psychiatry (Edgmont)"},{"key":"2025020405460543900_r11","doi-asserted-by":"crossref","first-page":"3729","DOI":"10.2174\/138161211798220918","article-title":"Cytokine signaling modulates blood-brain barrier function","volume":"17","author":"Pan","year":"2011","journal-title":"Curr. Pharm. Des."},{"key":"2025020405460543900_r12","doi-asserted-by":"crossref","first-page":"973","DOI":"10.2174\/1381612053381684","article-title":"Blood-brain barrier transport of cytokines: a mechanism for neuropathology","volume":"11","author":"Banks","year":"2005","journal-title":"Curr. Pharm. Des."},{"key":"2025020405460543900_r13","doi-asserted-by":"crossref","first-page":"20362","DOI":"10.1038\/s41598-019-56994-8","article-title":"Characterization of potential biomarkers of reactogenicity of licensed antiviral vaccines: randomized controlled clinical trials conducted by the BIOVACSAFE consortium","volume":"9","author":"Weiner","year":"2019","journal-title":"Sci. Rep."},{"key":"2025020405460543900_r14","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.toxlet.2011.03.001","article-title":"Progress in understanding adjuvant immunotoxicity mechanisms","volume":"203","author":"Batista-Duharte","year":"2011","journal-title":"Toxicol. Lett."},{"key":"2025020405460543900_r15","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s40264-015-0350-4","article-title":"Comparative safety of vaccine adjuvants: a summary of current evidence and future needs","volume":"38","author":"Petrovsky","year":"2015","journal-title":"Drug Saf."},{"key":"2025020405460543900_r16","first-page":"114","article-title":"Lost in translation: animal models and clinical trials in cancer treatment","volume":"6","author":"Mak","year":"2014","journal-title":"Am. J. Transl. Res."},{"key":"2025020405460543900_r17","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.bcp.2013.08.006","article-title":"Animal models of human disease: challenges in enabling translation","volume":"87","author":"McGonigle","year":"2014","journal-title":"Biochem. Pharmacol."},{"key":"2025020405460543900_r18","doi-asserted-by":"crossref","first-page":"469","DOI":"10.30802\/AALAS-JAALAS-19-000139","article-title":"Importance of systematic reviews and meta-analyses of animal studies: challenges for animal-to-human translation","volume":"59","author":"Bahadoran","year":"2020","journal-title":"J. Am. Assoc. Lab. Anim. Sci."},{"key":"2025020405460543900_r19","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jim.2006.07.023","article-title":"International validation of pyrogen tests based on cryopreserved human primary blood cells","volume":"316","author":"Schindler","year":"2006","journal-title":"J. Immunol. Methods"},{"key":"2025020405460543900_r20","doi-asserted-by":"crossref","first-page":"4859","DOI":"10.1016\/j.vaccine.2012.05.002","article-title":"Use of human MonoMac6 cells for development of in vitro assay predictive of adjuvant safety in vivo","volume":"30","author":"Zaitseva","year":"2012","journal-title":"Vaccine"},{"key":"2025020405460543900_r21","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/026119290903701S05","article-title":"An immunologic model for rapid vaccine assessment\u2014a clinical trial in a test tube","volume":"37","author":"Higbee","year":"2009","journal-title":"Altern. Lab. Anim."},{"key":"2025020405460543900_r22","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.biologicals.2012.10.005","article-title":"Potential use of inflammation and early immunological event biomarkers in assessing vaccine safety","volume":"41","author":"Mastelic","year":"2013","journal-title":"Biologicals"},{"key":"2025020405460543900_r23","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/j.1365-2567.2009.03237.x","article-title":"Assessing the immunopotency of Toll-like receptor agonists in an in vitro tissue-engineered immunological model","volume":"130","author":"Ma","year":"2010","journal-title":"Immunology"},{"key":"2025020405460543900_r24","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1177\/1076029614562037","article-title":"Evaluation of immunostimulatory potential of branded and US-generic enoxaparins in an in vitro human immune system model","volume":"21","author":"Luna","year":"2015","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"2025020405460543900_r25","doi-asserted-by":"crossref","first-page":"bbab320","DOI":"10.1093\/bib\/bbab320","article-title":"Application of artificial intelligence and machine learning for COVID-19 drug discovery and vaccine design","volume":"22","author":"Lv","year":"2021","journal-title":"Brief Bioinform."},{"key":"2025020405460543900_r26","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/978-1-0716-1884-4_6","article-title":"Artificial intelligence in vaccine and drug design","volume":"2410","author":"Thomas","year":"2022","journal-title":"Methods Mol. Biol."},{"key":"2025020405460543900_r27","doi-asserted-by":"crossref","first-page":"312","DOI":"10.3390\/ijms18020312","article-title":"Enhancing the biological relevance of machine learning classifiers for reverse vaccinology","volume":"18","author":"Heinson","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"2025020405460543900_r28","doi-asserted-by":"crossref","first-page":"3804","DOI":"10.1021\/acs.jcim.1c00460","article-title":"Development of machine learning models and the discovery of a new antiviral compound against yellow fever virus","volume":"61","author":"Gawriljuk","year":"2021","journal-title":"J. Chem. Inf. Model."},{"key":"2025020405460543900_r29","first-page":"20200319","article-title":"Predicting the short-term success of human influenza virus variants with machine learning","volume":"287","author":"Hayati","year":"2020","journal-title":"Proc. Biol. Sci."},{"key":"2025020405460543900_r30","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.1080\/21645515.2021.1940651","article-title":"Risk factors for carriage of meningococcus in third-level students in Ireland: an unsupervised machine learning approach","volume":"17","author":"Drew","year":"2021","journal-title":"Hum. Vaccin. Immunother."},{"key":"2025020405460543900_r31","doi-asserted-by":"crossref","first-page":"5487","DOI":"10.1016\/j.vaccine.2017.03.099","article-title":"The in vitro MIMIC\u00ae platform reflects age-associated changes in immunological responses after influenza vaccination","volume":"35","author":"Dauner","year":"2017","journal-title":"Vaccine"},{"key":"2025020405460543900_r32","doi-asserted-by":"crossref","first-page":"e0197478","DOI":"10.1371\/journal.pone.0197478","article-title":"Evaluation of the innate immunostimulatory potential of originator and non-originator copies of insulin glargine in an in vitro human immune model","volume":"13","author":"Luna","year":"2018","journal-title":"PLoS One"},{"key":"2025020405460543900_r33","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa2028436","article-title":"Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults","volume":"383","author":"Anderson","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"2025020405460543900_r34","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1016\/j.vaccine.2021.02.007","article-title":"A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine","volume":"39","author":"Chu","year":"2021","journal-title":"Vaccine"},{"key":"2025020405460543900_r35","article-title":"A study to evaluate efficacy, safety, and immunogenicity of mRNA-1273 vaccine in adults aged 18 years and older to prevent COVID-19","author":"ModernaTX, Inc.","year":"2023"},{"key":"2025020405460543900_r36","article-title":"Guidance for industry: toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials","author":"US Food and Drug Administration","year":"2007"},{"key":"2025020405460543900_r37","doi-asserted-by":"crossref","first-page":"e45185","DOI":"10.1371\/journal.pone.0045185","article-title":"CD80 and CD86 differentially regulate mechanical interactions of T-cells with antigen-presenting dendritic cells and B-cells","volume":"7","author":"Lim","year":"2012","journal-title":"PLoS One"},{"key":"2025020405460543900_r38","doi-asserted-by":"crossref","first-page":"5890","DOI":"10.4049\/jimmunol.180.9.5890","article-title":"CD83 expression in CD4+ T cells modulates inflammation and autoimmunity","volume":"180","author":"Reinwald","year":"2008","journal-title":"J. Immunol."},{"key":"2025020405460543900_r39","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.4049\/jimmunol.162.4.2044","article-title":"Human effector memory T cells express CD86: a functional role in naive T cell priming","volume":"162","author":"Jeannin","year":"1999","journal-title":"J. Immunol."},{"key":"2025020405460543900_r40","doi-asserted-by":"crossref","first-page":"5574","DOI":"10.1128\/IAI.00834-06","article-title":"Expression of the lipopolysaccharide-modifying enzymes PagP and PagL modulates the endotoxic activity of Bordetella pertussis","volume":"74","author":"Geurtsen","year":"2006","journal-title":"Infect. Immun."},{"key":"2025020405460543900_r41","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.micinf.2007.04.015","article-title":"Consequences of the expression of lipopolysaccharide-modifying enzymes for the efficacy and reactogenicity of whole-cell pertussis vaccines","volume":"9","author":"Geurtsen","year":"2007","journal-title":"Microbes Infect."},{"key":"2025020405460543900_r42","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.coi.2016.10.005","article-title":"Early innate immune responses to bacterial LPS","volume":"44","author":"Rosadini","year":"2017","journal-title":"Curr. Opin. Immunol."},{"key":"2025020405460543900_r43","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jaci.2005.05.036","article-title":"Innate immune responses to infection","volume":"116","author":"Tosi","year":"2005","journal-title":"J. Allergy Clin. Immunol."},{"key":"2025020405460543900_r44","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.jaci.2016.06.033","article-title":"Interleukins (from IL-1 to IL-38), interferons, transforming growth factor \u03b2, and TNF-\u03b1: receptors, functions, and roles in diseases","volume":"138","author":"Akdis","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"2025020405460543900_r45","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1006\/smim.1998.0138","article-title":"Role of early cytokines, including alpha and beta interferons (IFN-\u03b1\/\u03b2), in innate and adaptive immune responses to viral infections","volume":"10","author":"Biron","year":"1998","journal-title":"Semin. Immunol."},{"key":"2025020405460543900_r46","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1016\/j.vaccine.2004.03.010","article-title":"Reactogenicity of acellular pertussis vaccine in 4-year-olds in The Netherlands","volume":"22","author":"Keijzer-Veen","year":"2004","journal-title":"Vaccine"},{"key":"2025020405460543900_r47","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.3390\/cancers12113251","article-title":"Adverse event burden score\u2014a versatile summary measure for cancer clinical trials","volume":"12","author":"Le-Rademacher","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2025020405460543900_r48","doi-asserted-by":"crossref","first-page":"8489","DOI":"10.3390\/rs70708489","article-title":"On the importance of training data sample selection in random forest image classification: a case study in peatland ecosystem mapping","volume":"7","author":"Millard","year":"2015","journal-title":"Remote Sens."},{"key":"2025020405460543900_r49","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.rse.2009.12.004","article-title":"Prediction of species-specific forest inventory attributes using nonparametric semi-individual tree crown approach based on fused airborne laser scanning and multi-spectral data","volume":"114","author":"Breidenbach","year":"2010","journal-title":"Remote Sens. Environ."},{"key":"2025020405460543900_r50","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.4161\/hv.28666","article-title":"A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine (I)","volume":"10","author":"Prymula","year":"2014","journal-title":"Hum. Vaccin. Immunother."},{"key":"2025020405460543900_r51","doi-asserted-by":"crossref","first-page":"5206","DOI":"10.1016\/j.vaccine.2014.07.049","article-title":"A randomized, phase 1\/2 trial of the safety, tolerability, and immunogenicity of bivalent rLP2086 meningococcal B vaccine in healthy infants","volume":"32","author":"Martinon-Torres","year":"2014","journal-title":"Vaccine"},{"key":"2025020405460543900_r52","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1002\/art.24882","article-title":"DNA demethylation at specific CpG sites in the IL1B promoter in response to inflammatory cytokines in human articular chondrocytes","volume":"60","author":"Hashimoto","year":"2009","journal-title":"Arthritis Rheum."},{"key":"2025020405460543900_r53","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1089\/dst.2012.0006","article-title":"In vitro biomimetic model of the human immune system for predictive vaccine assessments","volume":"1","author":"Drake","year":"2012","journal-title":"Disrupt. Sci. Technol."},{"key":"2025020405460543900_r54","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1017\/CBO9780511576706.004","volume-title":"Acute Pain Management","author":"Ghori","year":"2009"},{"key":"2025020405460543900_r55","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/09629350120054518","article-title":"Anti-inflammatory cytokines in asthma and allergy: interleukin-10, interleukin-12, interferon-\u03b3","volume":"10","author":"Chung","year":"2001","journal-title":"Mediators Inflamm."},{"key":"2025020405460543900_r56","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3389\/fmed.2019.00119","article-title":"Biomarkers for immune checkpoint inhibitor-mediated tumor response and adverse events","volume":"6","author":"Nakamura","year":"2019","journal-title":"Front. Med. (Lausanne)"},{"key":"2025020405460543900_r57","doi-asserted-by":"crossref","first-page":"13797","DOI":"10.1038\/s41598-019-50310-0","article-title":"Comparative transcriptomics between species attributes reactogenicity pathways induced by the capsular group B meningococcal vaccine, 4CMenB, to the membrane-bound endotoxin of its outer membrane vesicle component","volume":"9","author":"Sheerin","year":"2019","journal-title":"Sci. Rep."},{"key":"2025020405460543900_r58","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s10753-010-9208-1","article-title":"Inflammatory cytokines imbalance in the very early phase of acute coronary syndrome: correlations with angiographic findings and in-hospital events","volume":"34","author":"Brunetti","year":"2011","journal-title":"Inflammation"},{"key":"2025020405460543900_r59","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41541-022-00439-3","article-title":"Circulating extracellular vesicle microRNAs associated with adverse reactions, proinflammatory cytokine, and antibody production after COVID-19 vaccination","volume":"7","author":"Miyashita","year":"2022","journal-title":"NPJ Vaccines"},{"key":"2025020405460543900_r60","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2471\/BLT.10.079426","article-title":"Intradermal delivery of vaccines: potential benefits and current challenges","volume":"89","author":"Hickling","year":"2011","journal-title":"Bull. World Health Organ."},{"key":"2025020405460543900_r61","first-page":"381","article-title":"Influenza vaccination: options and issues","volume":"11","author":"Wong","year":"2005","journal-title":"Hong Kong Med. J."},{"key":"2025020405460543900_r62","doi-asserted-by":"crossref","first-page":"e2035693","DOI":"10.1001\/jamanetworkopen.2020.35693","article-title":"Immunogenicity and safety of reduced-dose intradermal vs intramuscular influenza vaccines: a systematic review and meta-analysis","volume":"4","author":"Egunsola","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"2025020405460543900_r63","doi-asserted-by":"crossref","first-page":"5666","DOI":"10.1016\/j.vaccine.2011.06.010","article-title":"Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone\u00ae) administered by intradermal and intramuscular route in healthy adults","volume":"29","author":"Frenck","year":"2011","journal-title":"Vaccine"},{"key":"2025020405460543900_r64","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/gene.2008.80","article-title":"Integrated analysis of genetic and proteomic data identifies biomarkers associated with adverse events following smallpox vaccination","volume":"10","author":"Reif","year":"2009","journal-title":"Genes Immun."},{"key":"2025020405460543900_r65","doi-asserted-by":"crossref","first-page":"909406","DOI":"10.1155\/2015\/909406","article-title":"Application of \u201csystems vaccinology\u201d to evaluate inflammation and reactogenicity of adjuvanted preventative vaccines","volume":"2015","author":"Lewis","year":"2015","journal-title":"J. Immunol. Res."},{"key":"2025020405460543900_r66","first-page":"406","article-title":"Shingrix: a new herpes zoster vaccine","volume":"44","author":"Maltz","year":"2019","journal-title":"P T."},{"key":"2025020405460543900_r67","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1080\/21645515.2017.1317410","article-title":"A critical appraisal of \u201cShingrix\u201d, a novel herpes zoster subunit vaccine (HZ\/Su or GSK1437173A) for varicella zoster virus","volume":"13","author":"Bharucha","year":"2017","journal-title":"Hum. Vaccin. Immunother."},{"key":"2025020405460543900_r68","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.coi.2019.02.009","article-title":"Understanding the immunology of Shingrix, a recombinant glycoprotein E adjuvanted herpes zoster vaccine","volume":"59","author":"Heineman","year":"2019","journal-title":"Curr. Opin. Immunol."},{"key":"2025020405460543900_r69","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"2025020405460543900_r70","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older","volume":"375","author":"Cunningham","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"2025020405460543900_r71","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41541-022-00467-z","article-title":"An adjuvanted zoster vaccine elicits potent cellular immune responses in mice without QS21","volume":"7","author":"Nam","year":"2022","journal-title":"NPJ Vaccines"},{"key":"2025020405460543900_r72","doi-asserted-by":"crossref","first-page":"4420","DOI":"10.1016\/j.vaccine.2008.05.090","article-title":"The safety and tolerability of an HIV-1 DNA prime-protein boost vaccine (DP6-001) in healthy adult volunteers","volume":"26","author":"Kennedy","year":"2008","journal-title":"Vaccine"},{"key":"2025020405460543900_r73","doi-asserted-by":"crossref","first-page":"926","DOI":"10.4049\/jimmunol.168.2.926","article-title":"Monophosphoryl lipid A activates both human dendritic cells and T cells","volume":"168","author":"Ismaili","year":"2002","journal-title":"J. Immunol."},{"key":"2025020405460543900_r74","doi-asserted-by":"crossref","first-page":"152905","DOI":"10.1016\/j.phymed.2019.152905","article-title":"Updated insights into the mechanism of action and clinical profile of the immunoadjuvant QS-21: a review","volume":"60","author":"Lacaille-Dubois","year":"2019","journal-title":"Phytomedicine"},{"key":"2025020405460543900_r75","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41541-017-0027-3","article-title":"Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFN\u03b3 response promoting vaccine immunogenicity. [Published erratum appears in 2018 NPJ Vaccines 3: 13.]","volume":"2","author":"Coccia","year":"2017","journal-title":"NPJ Vaccines"}],"container-title":["The Journal of Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/212\/5\/904\/61474824\/ji2300185.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/212\/5\/904\/61474824\/ji2300185.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T05:48:44Z","timestamp":1738648124000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jimmunol\/article\/212\/5\/904\/7926074"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,26]]},"references-count":75,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,3,1]]}},"URL":"https:\/\/doi.org\/10.4049\/jimmunol.2300185","relation":{},"ISSN":["0022-1767","1550-6606"],"issn-type":[{"value":"0022-1767","type":"print"},{"value":"1550-6606","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,3]]},"published":{"date-parts":[[2024,1,26]]}}}